The LimiTEC trial explored teclistamab discontinuation in multiple myeloma, showing comparable outcomes to continuous therapy with a median PFS of 19.9 months. Fixed-duration therapy may reduce ...
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
Objectives Delays in cancer diagnosis for patients with non-specific symptoms (NSSs) lead to poorer outcomes. Rapid Diagnostic Clinics (RDCs) expedite care, but most NSS patients do not have cancer, ...
Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...
Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting ...
Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...
Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating ...
Myeloma specialist Dr. Urvi Shah is researching the role that whole-food and plant-based diets may play in slowing the progression of certain conditions into multiple myeloma. Many people who are ...
Arrivals to Guam dropped by 3% from just last year and more challenges could be ahead following multiple Korean media outlets reporting only three to four passengers on 180-seater aircraft flying the ...
Arrivals to Guam dropped by 3% from just last year and more challenges could be ahead following multiple Korean media outlets reporting only three to four passengers on 180-seater aircraft flying the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback